<DOC>
	<DOCNO>NCT02197416</DOCNO>
	<brief_summary>This open-label , single arm prospective cohort study assess safety dabigatran etexilate secondary prevention venous thromboembolism paediatric patient . Children 0 less 18 year age eligible participate .</brief_summary>
	<brief_title>Safety Dabigatran Etexilate Blood Clot Prevention Children</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dabigatran</mesh_term>
	<criteria>Inclusion criterion : Male female subject 0 less 18 year age time inform consent / assent Previously document objective diagnosis VTE , follow complete course initial VTE treatment least 3 month ( case VKA intend INR 2 3 ) complete study treatment ( i.e . reach Visit 8 ) 1160.106 trial . Patients , treatment phase 1160.106 trial switch dabigatran etexilate SOC arm reason , eligible study . Presence unresolved clinical risk factor require anticoagulation secondary VTE prevention ( e.g . central venous line , underlie disease , thrombophilia , etc . ) Written informed consent form ( ICF ) provide patient 's parent legal guardian assent provide patient ( applicable ) time ICF signature accord local regulation . Further inclusion criterion apply Exclusion criterion : Conditions associate increase risk bleed Renal dysfunction ( eGFR &lt; 80 mL/min/1.73m2 use Schwartz formula ) requirement dialysis Active infective endocarditis Subjects mechanical biological heart valve prosthesis Hepatic disease : Active liver disease , include know active hepatitis A , B C Persistent alanine aminotransferase ( ALT ) aspartate transaminase ( AST ) alkaline phosphatase ( AP ) &gt; 3 Ã— upper limit normal ( ULN ) within 3 month screen Pregnant breast feeding female . Females reach menarche use acceptable method birth control , plan continue use method throughout study / agree adhere pregnancy test require protocol Patients age group 0 &lt; 2 year gestational age birth &lt; 37 week body weight low 3rd percentile Anemia ( hemoglobin &lt; 80g/L ) thrombocytopenia ( platelet count &lt; 80 x 109/L ) screening . Transfusions screen period allow , provide satisfactory hemoglobin platelet level attain prior visit 2 Patients take restricted medication prior first dose study medication Patients receive investigational drug past 30 day prior screen , except patient complete treatment period ( Visit 8 ) 1160.106 trial Patients allergic/sensitive component study medication include solvent Patients parents/legal guardian consider unreliable participate trial per investigator judgment condition would present safety hazard patient base investigator judgment Further exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>